Morgan Stanley Sees US Market Acceleration Driving Upside Potential for Edwards Lifesciences Corp.

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on

. In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.” Edwards Lifesciences Corp. closed on Tuesday at $84.44.